New Brand Launch: Biocon introducing KRABEVA, a biosimilar Bevacizumab
Posted on24 Nov 2017
Comments0
Biocon Ltd, Asia’s premier biopharmaceuticals company, has launched KRABEVA, a biosimilar Bevacizumab for the treatment of patients with metastatic colorectal cancer and... Read More
Drug majors Mylan and Biocon’s biosimilar trastuzumab close to USFDA approval
Posted on17 Jul 2017
Comments0
Drug majors Mylan and Biocon on Friday said the US health regulator’s Oncologic Drugs Advisory Committee (ODAC) has recommended approval for their... Read More
Learning from Remsima, A Remicade biosimilar
Posted on16 Feb 2016
TagsA Remicade biosimilar, biocon's biosimilar, Biosimilar, highly similar drugs, Neupogen, Remicade biosimilar, Remsima, Zarxio
Comments0
USFDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to... Read More